Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche, Genentech Join Recursion Pharmaceuticals to Advance Neuroscience, Oncology Medicines

12/07/2021 | 10:37pm EST


ę MT Newswires 2021
All news about ROCHE HOLDING AG
01/28FDA Approves Genentech's Vabysmo, the First Bispecific Antibody for the Eye, to Treat T..
BU
01/28REMINDER : Invitation to Roche's Full Year Results 2021 Presentation
PU
01/26PTC Therapeutics - FDA Grants Evrysdi Priority Review Based on Results from Treating Pr..
AQ
01/26ROCHE HOLDINGS AG : Deutsche Bank keeps its Buy rating
MD
01/26ROCHE HOLDINGS AG : Goldman Sachs reiterates its Buy rating
MD
01/26ROCHE HOLDINGS AG : JP Morgan reiterates its Neutral rating
MD
01/25The Lancet Publishes Studies Showing Genentech's Faricimab Improved and Maintained Visi..
AQ
01/25Roche's Spinal Muscular Atrophy Drug Wins US FDA Priority Review
MT
01/25Genentech's Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Sympto..
BU
01/25Roche's Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomati..
AQ
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 62 207 M 66 785 M 66 785 M
Net income 2021 15 017 M 16 123 M 16 123 M
Net Debt 2021 6 627 M 7 115 M 7 115 M
P/E ratio 2021 19,7x
Yield 2021 2,79%
Capitalization 287 B 309 B 308 B
EV / Sales 2021 4,72x
EV / Sales 2022 4,67x
Nbr of Employees 101 465
Free-Float -
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 355,45 CHF
Average target price 407,45 CHF
Spread / Average Target 14,6%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Pascale Schmidt Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-6.24%308 691
JOHNSON & JOHNSON0.42%452 254
PFIZER, INC.-7.99%304 947
ABBVIE INC.1.86%243 826
ELI LILLY AND COMPANY-11.27%222 206
NOVO NORDISK A/S-13.07%218 259